ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung - Cancer

July 2, 2018
This video demonstrates a robotic right upper lobectomy, performed using the Cerfolio method of port placement.
June 27, 2018
The authors demonstrate a posterobasal anatomical segmentectomy of the left lower lobe, one of the most challenging sublobar resections through uniportal VATS.
June 18, 2018
The author reviews the evaluation, staging, and thought process of disease management for a patient with oligometastatic lung cancer, focusing on the VATS right middle lobe technique, a review of the literature, and current therapeutic options.
June 8, 2018
Patient Care and General Interest A charity bazaar raised money for a Shanghai Chest Hospital project that offers free heart surgery to children with congenital heart disease in China.
May 31, 2018
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival.  Tumor mutational burden was a marker for patient selection for immunotherapy.
May 30, 2018
The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.
May 25, 2018
Find it here: The 26th ESTS Meeting in Ljubljana, Slovenia.
May 23, 2018
The age-specific incidence of non-small cell lung cancer has reversed in individuals born since the 1960s, with women now having a higher incidence than men.  This trend is not explained by differences in smoking habits.
May 23, 2018
This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer.  The safety profile was adequate, 20 of 21 patients underwent complete resection, and the pathologic major response rate was 45%.   The response was similar regardless of PD-L1 status, and response was related to
May 23, 2018
The author demonstrates a uniportal fissureless approach to resect the anterior segment of the right upper lobe, followed by lymph node dissection.

Pages